<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Parkinson's Disease BRA â€” ArcaScience | Dopaminergic &amp; Disease-Modifying Therapy Benefit-Risk Analysis</title>
  <meta name="description" content="AI-driven benefit-risk analysis for Parkinson's Disease therapies. Comprehensive BRA for levodopa optimization, MAO-B inhibitors, alpha-synuclein-targeting immunotherapies, gene therapies, and device-aided treatments in PD.">

  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">
      <a href="/" aria-label="ArcaScience home"><img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32"></a>
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>
        <div style="position: relative;"><a href="/platform-overview" class="arca-nav-link">Platform</a></div>
        <div style="position: relative;"><a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions</a></div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/evidence-case-studies-hub" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Case Studies</a>
            <a href="/evidence-publications" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Publications</a>
            <a href="/evidence-metrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Platform Metrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/about" class="arca-nav-link">Company <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 200px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/about" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">About ArcaScience</a>
            <a href="/leadership" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Leadership</a>
            <a href="/careers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Careers</a>
            <a href="/science-methodology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Science &amp; Methodology</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/resources" class="arca-nav-link">Resources <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; right: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/resources" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Resource Hub</a>
            <a href="/resources-whitepapers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Whitepapers</a>
            <a href="/resources-webinars" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Webinars &amp; Events</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/resources-faq" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">FAQ</a>
            <a href="/resources-glossary" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Glossary</a>
          </div>
        </div>
      </div>
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">Talk to a Scientist</a>
    </div>
  </nav>

  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- HERO -->
    <section class="arca-bg-blue-900" style="position: relative; overflow: hidden; padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="position: absolute; top: -100px; right: -100px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(13, 124, 107, 0.12) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 8s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -80px; left: -80px; width: 400px; height: 400px; background: radial-gradient(circle, rgba(59, 125, 216, 0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 10s ease-in-out infinite reverse; z-index: 0;"></div>

      <svg width="420" height="320" viewBox="0 0 420 320" fill="none" aria-hidden="true" style="position: absolute; right: -20px; top: 50%; transform: translateY(-50%); opacity: 0.12; pointer-events: none; z-index: 0;">
        <circle cx="210" cy="160" r="16" stroke="rgba(13,124,107,0.5)" stroke-width="1.5" fill="none"/>
        <circle cx="210" cy="160" r="6" fill="rgba(13,124,107,0.3)"/>
        <circle cx="290" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="290" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <line x1="210" y1="160" x2="290" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="290" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
      </svg>

      <div style="position: relative; z-index: 1; max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/ta-neurology" style="color: rgba(255,255,255,0.65); text-decoration: none;">Neurology</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Parkinson&rsquo;s Disease</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">Neurology &rsaquo; Parkinson&rsquo;s Disease</p>
          <h1 class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            Dopaminergic &amp; Disease-Modifying Therapy Benefit-Risk Analysis for Parkinson&rsquo;s Disease
          </h1>
          <p class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            Parkinson&rsquo;s disease treatment spans decades of dopaminergic therapy optimization, emerging alpha-synuclein immunotherapies, and device-aided interventions. ArcaScience provides comprehensive BRA across levodopa formulations, MAO-B inhibitors, prasinezumab and other anti-alpha-synuclein agents, gene therapies, and device-aided treatments including DBS and LCIG.
          </p>
          <div style="display: flex; gap: 16px; flex-wrap: wrap;">
            <a href="/platform-overview" class="arca-btn-primary-inverted">See Platform</a>
            <a href="/contact?disease=parkinsons" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Request Demo</a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY STATISTICS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="10000000" data-countup-suffix="+">0</span>
            <p class="arca-caption">People living with PD worldwide</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="1900" data-countup-suffix="+">0</span>
            <p class="arca-caption">PD therapeutic trials analyzed</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="40" data-countup-suffix="%">0</span>
            <p class="arca-caption">Patients develop motor fluctuations within 5 years</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="17" data-countup-suffix="%">0</span>
            <p class="arca-caption">Impulse control disorder prevalence on dopamine agonists</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DISEASE OVERVIEW -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Disease Overview</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">Why Parkinson&rsquo;s Disease Therapies Demand Specialized BRA</h2>
          <p class="arca-body-lg arca-text-grey-600">
            Parkinson&rsquo;s disease requires treatment over decades, during which motor complications emerge, neuropsychiatric adverse effects accumulate, and patients transition through oral, device-aided, and potentially disease-modifying therapies. The benefit-risk balance shifts continuously with disease progression, demanding dynamic BRA frameworks that account for evolving treatment goals from symptom control to neuroprotection.
          </p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Motor Fluctuations and Dyskinesia Management</h3>
            <p class="arca-body-sm arca-text-grey-600">
              After 5 years of levodopa therapy, approximately 40% of patients develop motor fluctuations (on-off phenomena) and levodopa-induced dyskinesia. Managing these requires complex polypharmacy with COMT inhibitors (opicapone, entacapone), MAO-B inhibitors (safinamide, rasagiline), and adjunctive dopamine agonists, each introducing their own safety signals. BRA must model the cumulative burden of multi-drug regimens and the evolving benefit-risk ratio as disease progresses.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Neuropsychiatric Adverse Effects</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Dopaminergic therapies carry substantial neuropsychiatric risk. Dopamine agonists (pramipexole, ropinirole, rotigotine) cause impulse control disorders (pathological gambling, hypersexuality, compulsive spending) in up to 17% of patients. Advanced PD patients on high-dose levodopa develop hallucinations and psychosis requiring pimavanserin or clozapine, creating cascading BRA complexity. Deep brain stimulation (DBS) introduces additional neuropsychiatric considerations including mood changes and apathy.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Disease-Modifying and Gene Therapy Risks</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Alpha-synuclein-targeting immunotherapies (prasinezumab/PASADENA, cinpanemab) and gene therapies (AAV-based GBA1, AADC gene therapy/SPARK) represent a paradigm shift from symptomatic to disease-modifying treatment. These novel modalities introduce unprecedented BRA challenges: infusion reactions and immunogenicity for monoclonal antibodies, irreversibility and long-term expression safety for gene therapies, and the fundamental challenge of measuring disease modification versus symptomatic benefit in trial endpoints.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ARCASCIENCE APPROACH -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-grey-50 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">How ArcaScience Addresses Parkinson&rsquo;s Disease BRA</h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">Our modules are configured with PD-specific therapeutic data, motor complication prediction models, neuropsychiatric safety algorithms, and regulatory templates for both symptomatic and disease-modifying therapy submissions.</p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card arca-card-colored-top is-data" data-animate="slide-up">
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">PD Therapeutic Data</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">1,900+ PD clinical trials including SPARK (AADC gene therapy), PASADENA and PADOVA (prasinezumab), EXPAND-PD, and landmark levodopa optimization studies. Comprehensive safety databases spanning dopaminergic therapies, MAO-B inhibitors, COMT inhibitors, and emerging alpha-synuclein immunotherapies. Integrated device-aided therapy registries covering DBS outcomes, LCIG (Duodopa) safety, and subcutaneous apomorphine pump data from real-world cohorts of 100,000+ patients.</p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">Explore Data Engine <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-card arca-card-colored-top is-analytics" data-animate="slide-up">
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">PD-Specific AI Safety Models</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">AI models for motor fluctuation prediction using levodopa dose trajectories and wearing-off patterns. Impulse control disorder risk stratification for dopamine agonist therapies using demographic, genetic, and treatment-related predictors. Dyskinesia severity modeling for levodopa dose optimization. Neuropsychiatric safety algorithms for hallucination and psychosis detection across all dopaminergic agents. Gene therapy long-term expression and immunogenicity monitoring models for AAV-based treatments.</p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">Explore AI Models <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-card arca-card-colored-top is-output" data-animate="slide-up">
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Neurology Regulatory Outputs</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">PSURs with dedicated sections for motor complication tracking, impulse control disorder surveillance, and neuropsychiatric adverse event monitoring. RMPs incorporating ICD screening protocols, DBS patient selection criteria, and gene therapy long-term follow-up plans. Disease-modification endpoint BRA documents supporting accelerated approval pathways. Post-marketing commitment reports aligned with FDA and EMA guidance on disease-modifying therapy endpoints and long-term gene therapy safety monitoring requirements.</p>
            <a href="/platform-outputs" class="arca-btn-tertiary">Explore Outputs <span class="arca-arrow">&rarr;</span></a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY METRICS -->
    <section class="arca-bg-blue-50 arca-bg-mesh" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">PD Intelligence</p>
          <h2 class="arca-display-sm">Platform Performance in Parkinson&rsquo;s Disease</h2>
        </div>
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="2900000000" data-countup-suffix="+">0</span>
            <p class="arca-caption arca-text-grey-600">PD safety data points tracked</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="64" data-countup-suffix="%">0</span>
            <p class="arca-caption arca-text-grey-600">Faster ICD signal detection vs. traditional methods</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="10">0</span>
            <p class="arca-caption arca-text-grey-600">PD therapy-class safety models deployed</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="7">0</span>
            <p class="arca-caption arca-text-grey-600">PD regulatory submissions supported</p>
          </div>
        </div>
      </div>
    </section>

    <!-- CASE EVIDENCE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">
          <div>
            <p class="arca-section-label">Case Evidence &mdash; Parkinson&rsquo;s Disease</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">Impulse Control Disorder Surveillance for Dopamine Agonist Therapy</h2>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">A pharma company needed to conduct comprehensive post-marketing benefit-risk evaluation for their extended-release dopamine agonist, with particular focus on impulse control disorders (pathological gambling, compulsive shopping, hypersexuality) that were significantly under-reported in clinical trials but emerging at higher rates in real-world pharmacovigilance data and patient advocacy reports.</p>
            </div>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Result</h3>
              <p class="arca-body-sm arca-text-grey-600">ArcaScience's AI models identified dose-dependent ICD risk patterns and demographic risk factors (younger age, male sex, history of substance use) 2.8x faster than standard FAERS disproportionality analysis. This enabled proactive label strengthening with ICD screening recommendations and dose ceiling guidance, preventing a potential regulatory referral and supporting a risk minimization strategy accepted by both FDA and EMA.</p>
            </div>
            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="2.8" data-countup-suffix="x">0</span>
                <p class="arca-caption arca-text-grey-600">Faster ICD risk pattern identification</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="38" data-countup-suffix="%">0</span>
                <p class="arca-caption arca-text-grey-600">Reduction in ICD-related treatment discontinuations</p>
              </div>
            </div>
            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">View All Case Studies <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--blue-400);">
              The ICD signal was growing in social media and patient forums well before it was statistically detectable in FAERS. ArcaScience's multi-source signal detection gave us 18 months of lead time to strengthen our label and implement screening recommendations, transforming what could have been a reactive crisis into a proactive patient safety initiative.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Global Head of Neuroscience Safety</p>
              <p class="arca-body-sm arca-text-grey-600">Mid-Cap Pharma Company</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- FAQ ACCORDION -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-teal-100 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Frequently Asked Questions</p>
          <h2 class="arca-display-sm">Parkinson&rsquo;s Disease Therapy BRA</h2>
        </div>
        <div style="max-width: 820px; margin: 0 auto;">
          <div class="arca-accordion" data-accordion="group">
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience model motor fluctuation risk over time?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Our platform uses longitudinal levodopa dose data, treatment duration, disease severity scores (UPDRS/MDS-UPDRS), and patient demographic profiles to predict the onset and progression of motor fluctuations and dyskinesia. AI models trained on 100,000+ patient-years of data identify wearing-off patterns, on-off transitions, and peak-dose dyskinesia trajectories, enabling proactive adjunctive therapy recommendations and supporting regulatory BRA for new formulations designed to provide more continuous dopaminergic stimulation.</p>
              </div>
            </div>
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Can the platform assess benefit-risk for alpha-synuclein immunotherapies?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Yes. Alpha-synuclein-targeting therapies like prasinezumab (PASADENA, PADOVA trials) represent a fundamentally new BRA paradigm. Our models address the unique challenge of measuring disease modification versus symptomatic benefit, analyzing composite endpoint sensitivity, biomarker-clinical correlations (DAT-SPECT imaging, serum neurofilament light chain), and infusion reaction/immunogenicity profiles. We also model the benefit-risk of treating patients earlier in disease course where toxicity tolerance is lower but disease-modification potential is highest.</p>
              </div>
            </div>
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience handle device-aided therapy BRA (DBS, LCIG)?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Device-aided therapies present unique BRA complexity due to surgical risk (DBS lead placement, PEJ tube insertion for LCIG), device-related complications (lead migration, tube occlusion, pump malfunction), and the irreversibility of some interventions. Our platform integrates DBS registry data covering stimulation-related neuropsychiatric effects (mood changes, speech impairment, apathy), LCIG polyneuropathy signals, and subcutaneous apomorphine infusion site reactions. Models support patient selection criteria development and informed consent frameworks required by regulatory authorities.</p>
              </div>
            </div>
            <div class="arca-accordion-item">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Does the platform cover gene therapy BRA for Parkinson&rsquo;s disease?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Yes. Gene therapies for PD, including AAV2-AADC (eladocagene exuparvovec/SPARK trial) and GBA1-targeted approaches, introduce unprecedented BRA challenges. Our platform models surgical delivery risks (stereotactic injection), AAV vector immunogenicity, long-term transgene expression durability and safety, and the theoretical risk of insertional mutagenesis. We provide 15-year follow-up BRA frameworks aligned with FDA and EMA long-term gene therapy safety guidance, and comparative models that position gene therapy benefit-risk against optimized medical therapy and DBS for advanced PD patients.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- CTA -->
    <section class="arca-cta-section" data-animate style="position: relative; overflow: hidden;">
      <div style="position: absolute; top: -60px; left: -60px; width: 300px; height: 300px; background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 7s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -40px; right: -40px; width: 250px; height: 250px; background: radial-gradient(circle, rgba(255,255,255,0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 9s ease-in-out infinite reverse; z-index: 0;"></div>
      <div style="position: relative; z-index: 1; max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">See ArcaScience Applied to Parkinson&rsquo;s Disease</h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">Request a demonstration focused on Parkinson&rsquo;s disease BRA. Our neuroscience specialists will present motor complication prediction models, impulse control disorder surveillance, alpha-synuclein immunotherapy BRA frameworks, and gene therapy long-term safety monitoring.</p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?disease=parkinsons" class="arca-btn-primary-inverted">Request PD Briefing</a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Explore the Platform <span class="arca-arrow">&rarr;</span></a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">
        <div><img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);"><p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.</p></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a><a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a><a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a><a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a><a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a><a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a><a href="/solution-post-marketing" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Post-Marketing</a><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a><a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a><a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a><a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a><a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a><a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a><a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a><a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a></nav></div>
      </div>
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">&copy; 2026 ArcaScience. All rights reserved.</p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <button data-back-to-top aria-label="Back to top"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg></button>

  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });
      document.querySelectorAll('[data-accordion] .arca-accordion-header').forEach(function(header) {
        header.addEventListener('click', function() {
          var content = this.nextElementSibling;
          var icon = this.querySelector('.arca-accordion-icon');
          var isOpen = content.style.display === 'block';
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-content').forEach(function(c) { c.style.display = 'none'; });
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-icon').forEach(function(i) { i.textContent = '+'; });
          if (!isOpen) { content.style.display = 'block'; icon.textContent = '\u2212'; }
        });
      });
    });
  </script>
</body>
</html>